INSULET CORP — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Insulet reported Q3 2026 revenue of $842 million, up 19.2% YoY (19.6% constant currency), slightly above guidance. Omnipod revenue grew 19.7% ($836.6M); U.S. up 14.7%, International up 31.7% (33% constant currency). Operating income reached $189.8M (22.5% margin, +590 bps YoY); adjusted net income $138M (+57.2% YoY); diluted EPS $2.03 vs. $1.24 prior year. Board approved $1B share repurchase program with ~$400M allocated to Q4 2026. FY 2026 guidance raised: Total Omnipod growth now 21.5–22.5% constant currency (prior 21–23%), Adjusted Operating Margin ~150 bps YoY expansion (prior ~100 bps).
Why this rating
Strong beat on guidance, 590 bps margin expansion, 60% EPS growth, and aggressive $1B buyback signal robust execution and confidence. Relative to $22.1B market cap, $842M quarterly revenue is material; margins expanding sharply. Material but not transformational at this scale.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.